The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination
- PMID: 3680299
- DOI: 10.1016/s0092-1157(87)80003-3
The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination
Abstract
Two different derivatives of the 17D strain of yellow fever (YF) vaccine virus, i.e. ALV-free seed virus 6676 and three consecutive vaccine lots, A, B and C, obtained from another seed, were compared in monkey neurovirulence tests using rhesus and cynomolgus monkeys. In addition the ALV-contaminated seed lot AB 237 was safety tested in rhesus monkeys. According to WHO clinical criteria for acceptability, lots A, B, C and lot AB 237 consistently passed, while lot 6676 passed some tests and failed others. In the same tests, quantitative clinical evaluation and histological examination of CNS gave more definitive and consistent data on the higher degree of neurovirulence of lot 6676. Especially differentiating histological findings were obtained from some anatomical structures of the CNS ('discriminator areas') and almost no difference was found between the products in the structures apparently most susceptible to YF virus ('target areas'). Although some of the target and discriminator areas were different, cynomolgus monkeys were not less susceptible than rhesus monkeys to YF vaccine virus. The use of a quantitative method of scoring specific lesions in CNS of monkeys and the comparison of the average scores of a YF vaccine lot under study with a 'reference' vaccine, which has proven to be safe and effective in humans, should provide for a more reproducible method of assessing vaccine neurovirulence.
Similar articles
-
Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys.Virology. 2003 Nov 10;316(1):55-63. doi: 10.1016/s0042-6822(03)00583-x. Virology. 2003. PMID: 14599790
-
Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.Vaccine. 1999 Apr 9;17(15-16):1869-82. doi: 10.1016/s0264-410x(98)00487-3. Vaccine. 1999. PMID: 10217584
-
Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblasts: yields, thermo and genetic stability, attenuation and immunogenicity.Vaccine. 2005 Mar 31;23(19):2501-12. doi: 10.1016/j.vaccine.2004.10.035. Vaccine. 2005. PMID: 15752837
-
Some aspects of the monkey neurovirulence test used for the assessment of oral poliovirus vaccines.Dev Biol Stand. 1993;78:61-70. Dev Biol Stand. 1993. PMID: 8388832 Review.
-
Review of the risks and benefits of yellow fever vaccination including some new analyses.Expert Rev Vaccines. 2012 Apr;11(4):427-48. doi: 10.1586/erv.12.6. Expert Rev Vaccines. 2012. PMID: 22551029 Review.
Cited by
-
Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.Vaccine. 2016 Dec 12;34(51):6597-6609. doi: 10.1016/j.vaccine.2016.06.071. Epub 2016 Jul 6. Vaccine. 2016. PMID: 27395563 Free PMC article. Review.
-
Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates.PLoS Negl Trop Dis. 2012;6(3):e1567. doi: 10.1371/journal.pntd.0001567. Epub 2012 Mar 20. PLoS Negl Trop Dis. 2012. PMID: 22448291 Free PMC article.
-
ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.J Virol. 2004 Nov;78(22):12497-507. doi: 10.1128/JVI.78.22.12497-12507.2004. J Virol. 2004. PMID: 15507637 Free PMC article.
-
Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.Springer Semin Immunopathol. 2006 Nov;28(3):239-53. doi: 10.1007/s00281-006-0042-3. Epub 2006 Sep 15. Springer Semin Immunopathol. 2006. PMID: 16977404 Free PMC article. Review.
-
Live Viral Vaccine Neurovirulence Screening: Current and Future Models.Vaccines (Basel). 2021 Jun 30;9(7):710. doi: 10.3390/vaccines9070710. Vaccines (Basel). 2021. PMID: 34209433 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources